3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
111
Neoplasms
8
Neoplasm Metastasis
6
Carcinoma, Intraductal, Noninfiltrating
6
Breast Carcinoma In Situ
4
Arthralgia
4
Advanced Breast Cancer
4
Osteoporosis
2
Multiple Endocrine Neoplasia Type 1
2
Breast Neoplasms, Male
2
Breast Cancer Metastatic
2
Triple Negative Breast Neoplasms
1
Sexual Dysfunction, Physiological
1
Seizures
1
Recurrence
1
Quality of Life
1
Patient Compliance
1
Pain
1
Ovarian Neoplasms
1
Obesity
1
Lethal Congenital Contracture Syndrome 2
1
Joint Diseases
1
Invasive Breast Cancer
1
Hypogonadism
1
Granulosa Cell Ovarian Cancer
1
Fractures, Bone
1
Erectile Dysfunction
1
Epilepsy
1
Bone Diseases, Metabolic
1
Bone Density
1
Interventions
Zoledronic Acid
5
Risedronic Acid
4
Vitamin D
3
Denosumab
3
Letrozole
2
Calcium
2
Toremifene
1
Radiography, Panoramic
1
Nutrition Assessment
1
Kyphoplasty
1
Ibandronic Acid
1
Health Promotion
1
Geritol
1
Exercise
1
Calcium Carbonate
1
Aromatase Inhibitors
1
Anastrozole
1
ARQ 197
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Bone Diseases, Metabolic
×
Anastrozole
×
Clear all
NCT00082277
2011-01-26
SABRE
AstraZeneca
Phase 4
Completed
237 enrolled